Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company.
“We are pleased to announce this agreement with K2 HealthVentures, a life sciences investment firm known for strategic investments in promising healthcare companies,” Daniel O’Connell, president and CEO of Acumen, said. “This financing provides us with additional operational flexibility during a period when we are laser-focused on execution. In particular, the funding will support our recently announced development program for a subcutaneous form of ACU193, including a Phase 1 study which we expect to initiate in mid-2024.”
“We are excited to partner with Acumen on this financing to support management’s vision of developing a potential best-in-class treatment for early Alzheimer’s Disease,” Nimesh Shah, managing director at K2 HealthVentures, said. “This financing follows our strategy of partnering with pioneering life science companies developing treatments that have the potential to transform lives.”
The loan agreement provides up to $50 million principal in term loans consisting of a first tranche of $30 million, which was funded at closing and a second tranche of up to $20 million which may be funded in installments upon the company’s request, subject to review by the lenders of certain information from the company and discretionary approval from the lenders. The term loan matures on Nov. 1, 2027 and may be extended to Nov. 1, 2028 if the company achieves certain financing milestones.
